ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Dentsply Sirona Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – XRAY

NEW YORK, June 15, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common stock of Dentsply Sirona Inc. (NASDAQ: XRAY) between June 9, 2021 and May 9, 2022, both dates inclusive (the “Class Period”), of the important August 1, 2022 lead plaintiff deadline. SO WHAT: If you purchased Dentsply […]

DW-5600GU-7

Casio to Release G-SHOCK Featuring Successive Master of G Characters

Signature characters brought back to life in camouflage design TOKYO, June 15, 2022 /PRNewswire/ — Casio Computer Co., Ltd. announced today the latest addition to its G-SHOCK shock-resistant watches. The DW-5600GU-7 features past characters from Master of G models designed for use on land and in the sea and air, all distilled into one timepiece. […]

Reinforcing Success – Fluidic Propulsive System™ Development & New Crowdfunding Initiative

EDMONDS, Wash., June 14, 2022 (GLOBE NEWSWIRE) — Today, Jetoptera announced the launch of their Regulation Crowdfunding raise via StartEngine. We are creating a transformative aerospace propulsion system and capability to evolve vertical takeoff and landing aircraft beyond propellers and rotors.

Jetoptera invites you to be the catalyst, a pioneer, and adventurer with us on this amazing journey to bring forth a safe, quiet multi-use method of propulsion which is focused on S/VTOL, small and medium helicopter replacement with missions spanning logistics, air ambulance, VIP transportation and commonplace aerial mobility, as well as on high-speed VTOL, and wing in ground effect maritime craft, that can scale to a vast array of sizes and applications.

“We are encouraged and enthusiastic about the extensive data we are collecting with the support of the US Air Force to refine the design of our new scalable prototype FPS™ based vehicles,” said Founder and CEO Dr. Andrei Evulet. “Advancements in such a transformational capability as Fluidic Propulsive Systems and their integration into advanced airframe designs demands our attention, focus and determination to make FPS™ propelled vehicles in the air, land and sea commonplace in the years to come.”

To learn more about your Jetoptera Crowdfunded investment opportunity, please go to https://www.startengine.com/jetoptera/

ABOUT JETOPTERA
Jetoptera is a propulsion system, drone, and aerial mobility startup with the vision to create a world where aerial mobility is commonplace. To that end, we have developed and demonstrated a unique Fluidic Propulsive System™ integrated with a novel airframe, protected by 60 granted and allowed patents and another 100+ pending. This has many advantages over other approaches: faster, simpler, quieter, more compact, and lower cost. Our distributed propulsion system lends itself naturally to our mission, to create vertical and short takeoff and landing (V/STOL) aircraft, with other applications such as wing in ground effect vehicles to enable unmatched speed, range, payload, and efficiency to transport cargo and people.

Contact
Todd Newton
Vice President
+1 (703) 589-3739
info@jetoptera.com

Facebook | LinkedIn

PM extends birthday greetings to Chinese President

Prime Minister Shehbaz Sharif says government is committed to complete Special Economic Zones at the earliest to ensure development and prosperity in the country.

Addressing a meeting at Rashakai Special Economic Zone in Rashakai on Wednesday, he said all problems and hurdles in the smooth execution of SEZs would be addressed on a priority basis.

The Prime Minister said focusing on establishing SEZs across the country would boost industrialization and exports and generate employment.

He said the solution to Pakistan’s economic problems is the massive industrialization and diversifying the export base. He said massive economic activity in the country would create employment, encourage exports and stimulate import substitution.

The Prime Minister said nine SEZs have been planned to be developed in Pakistan for promoting industrial infrastructural and technology transfer.

He invited the Chinese companies to invest in Pakistan. He said Chinese expertise in technology and the cheap labour of Pakistan could act in a balance to benefit both sides.

The Prime Minister proposed the launch of roadshows in China to highlight Pakistan’s potential for trade and investment.

He emphasized on sharing of expertise between the two countries and need to further augment development by exploring areas in Khyber Pukhtunkhwa and other parts of Pakistan.

He directed the authorities to follow the timelines of the projects related to SEZs and announced holding a virtual meeting in the future to sort out ways for improvement.

 

Source: Radio Pakistan

People-friendly Punjab budget worth Rs3226b unveiled

The people-friendly Punjab Budget with a total outlay of 3226 billion rupees for financial year 2022-23 was presented in Lahore on Wednesday.

Presenting the budget, Finance Minister, Sardar Owais Ahmad Khan Leghari said the total volume of the budget is 22 percent more than current fiscal year, out of which 1712 billion rupees have been allocated for Current Expenditures.

He said that total estimated Revenue for next fiscal year is 2521.29 billion rupees, while the province will get over 2020 billion rupees from the Federal Divisible Pool.

The Minister said 435.87 billion rupees have been allocated for Salaries, 312 billion rupees for pensions while 528 billion rupees for Local Governments.

The Finance Minister said no new tax has been levied in next fiscal year on account of Sales Tax on Services. He said Stamp Duty ratio has been proposed to enhance from current one percent to 2 percent to raise provincial revenue.

Owais Leghari said 35 percent of the Annual Development Program amounting to 240 billion rupees has been allocated for South Punjab, which will be spent on development projects.

 

Source: Radio Pakistan

Govt working tirelessly to provide relief to masses: Marriyum

Minister for Information and Broadcasting Marriyum Aurangzeb says the government is working tirelessly to provide relief to the people.

Addressing a news conference in Islamabad on Wednesday, the Information Minister said the past government of PTI was never interested in development but only looted the country, laundered money and illegally grabbed money of welfare trusts.

She said the last PTI government broke all records of corruption and did not complete development projects started before 2018 during the tenure of PML-N government.

Marriyum Aurangzeb said the present government is trying to complete the incomplete development projects to bring economic stability in the country.

She said the government is committed to clear the mess created by PTI and will steer the country on the path of progress and development.

She said if there was any foreign conspiracy, PTI Chairman Imran Khan should have presented evidence before the national security committee. She said Imran Khan keeps on changing narratives and when one narrative fails, he puts forth another.

 

Source: Radio Pakistan

Impulse Dynamics Announces First International Implants of the Optimizer Smart Mini System in Italy

MARLTON, N.J., June 14, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a commercial-stage medical device company focused on delivering our CCM therapy to people with heart failure, announced that the first implants in Europe for the newly launched Optimizer® Smart Mini device were recently completed in Italy. The company announced the launch of the new technology on April 29, 2022, and the first U.S. implants on May 10, 2022.

Dr. Stefano Guarracini, Head of Cardiology at the Synergo Casa di Cura Pierangeli Hospital in Pescara, Italy, described his experience with CCM therapy and his outlook for the Optimizer Smart Mini system after the first implant. “Starting in 2019, we had the opportunity to implant Optimizer devices in several patients with heart failure. We believe in the technology and consider CCM therapy to be the only option for many patients suffering from heart failure. We are excited now to be affiliated with the first European institution to have implanted the new Optimizer Smart Mini device and look forward to the simple but more advanced patient management experiences during implants and follow-ups going forward.”

Dr. Giovani Bisignani, with the Ospedale di Castrovillari, who completed his first implant almost simultaneously in the southern Italian province of Cosenza, said, “CCM therapy is a powerful weapon against heart failure. The cutting-edge technology of the new Optimizer Smart Mini along with its smaller, physiological shape allowed us to achieve efficient implantation and initiation of CCM therapy in even less time.”

In March 2022, the company announced that its quality management system received certification under the new European Union Medical Device Regulation. We believe that the launch of the Optimizer Smart Mini system is an example of the importance of a global infrastructure to support ongoing technology innovation and access. The new components of the Optimizer Smart Mini system are equally important across international markets, including a rechargeable battery with a 20-year life and new internal technology with improved programming and potential for remote monitoring in a smaller design to make the implant procedure easier for patients and physicians.

“The pace of this international rollout is a reflection of our commitment to delivering innovation that is relevant to patients worldwide,” said Mateusz Zelewski, MD, Impulse Dynamics’ Vice President International, “It is exciting to see how quickly we can increase access to new and better technology that offers hope for more patients living with heart failure.”

The Optimizer Smart Mini delivers CCM therapy, which consists of electric pulses applied to the heart between heartbeats and serves to enhance the performance of cardiac muscular contraction, making the heart work more efficiently without increasing the heart rate or the oxygen consumption of the cardiac muscle. CCM therapy is currently indicated in Europe to reduce hospitalizations and improve physical exercise tolerance, quality of life, and functional status for a large population of patients with systolic heart failure who remain symptomatic despite guideline-directed medical therapy.

To date, CCM therapy has already been used to treat over 7,000 patients worldwide and is available in 44 countries across the globe. The therapy has been studied in almost 2,000 patients and has appeared in more than 100 peer-reviewed journal articles. Ongoing studies are also underway to examine the safety and efficacy of CCM for patients suffering from heart failure with a left ventricular ejection fraction between 40 – 60%.

About Impulse Dynamics

Impulse Dynamics is dedicated to helping healthcare providers enhance the lives of people with heart failure by transforming how the condition is treated. The company is focused on delivering its proprietary CCM therapy, which is delivered by the company’s Optimizer Smart device, the CE-marked, and FDA-approved treatment verified to improve the quality of life for heart failure patients. CCM therapy is a safe, effective, and minimally invasive treatment option for many heart failure patients who otherwise have few effective options available to them.[1] To learn more, visit www.ImpulseDynamics.com, or follow the company on LinkedIn, Twitter, and Facebook.

Forward-looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy, and the absence of risks associated therewith; the ability for CCM therapy and our products to fill a significant unmet medical need for patients with heart failure; and the short-term and long-term benefits of the Optimizer Smart Mini and CCM therapy in patients with heart failure, as well as to the physicians treating those patients. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company’s future research and development costs, capital requirements and the company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer Smart and Optimizer Smart Mini systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the company’s ability to expand, manage and maintain its direct sales and marketing organization; the company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494150/

Attachments

Rex Richmond, Director (Media Relations)
Impulse Dynamics
856-642-9933
rrichmond@impulsedynamics.com

Harriss Currie, CFO (Investor Relations)
Impulse Dynamics
856-642-9933
hcurrie@impulsedynamics.com

Ian Segal, Public Relations
Impulse Dynamics
856-642-9933
isegal@impulsedynamics.com